In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097

Virology

Volumn 231, Issue 1, 1997, Pages 112-118

  Kleim, Jörg Peter ^a   Winkler, Irvin ^a   Rösner, Manfred ^a   Kirsch, Reinhard ^a   Rübsamen Waigmann, Helga ^b   Paessens, Arno ^b   Riess, Günther ^a  

^a SANOFI   (France)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; QUINOXALINE; RNA DIRECTED DNA POLYMERASE; TALVIRALINE;

ARTICLE; DRUG EFFECT; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PRIORITY JOURNAL; VIRUS MUTANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030926748     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8513     Document Type: Article

References (28)

1. Albert J., Wahlberg J., Leitner T., Escanilla D., Uhlén M. Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes. J. Virol. 68:1994;5918-5924.
2. Balzarini J., Karlsson A., Meichsner C., Paessens A., Riess G., De Clercq E., Kleim J.-P. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 68:1994;7986-7992.
3. J. Balzarini, H. Pelemans, G. Riess, M. Rösner, I. Winkler, E. De Clercq, J.-P. Kleim, 1996a, AZT-resistant HIV-1 strains subcultured in the combined presence of quinoxaline HBY 097 and lamivudine (3TC), retain marked sensitivity to HBY 097.
4. Balzarini J., Pelemans H., Karlsson A., De Clercq E., Kleim J.-P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA. 93:1996b;13152-13157.
5. Buckheit R. W., Fliakas-Boltz V., Decker W. D., Roberson J. L., Stup T. L., Pyle C. A., White E. L., McMahon J. B., Currens M. J., Boyd M. R., Bader J. P. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. 26:1995;117-132.
6. Condra J. H., Schleif W. A., Blahy O. M., Gabryelski L. J., Graham D. J., Quintero J. C., Rhodes A., Robbins H. L., Roth E., Shivaprakash M., Titus D., Yang T., Teppier H., Squires K. E., Deutsch P. J., Emini E. A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
7. De Clercq E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:1995;2491-2517.
8. L. M. Demeter, P. Gerondelis, A. Dexter, L. Berrios, G. Morse, S. Cox, W. Freimuth, R. C. Reichman, 1995, Combination therapy (Rx) with delavirdine (DLV) and ddI, but not AZT, fails to prevent the emergence of Y181C in nucleoside experienced patients (PTS) [Abstract 31].
9. Dueweke T. J., Pushkarskaya T., Poppe S. M., Swaney S. M., Zhao J. Q., Chen I. S. Y., Stevenson M., Tarpley W. G. A novel mutation in bisheteroarylpiperazine resistant HIV-1 reverse transcriptase confers increased sensitivity to other non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA. 90:1993;4713-4717.
10. Hargrave K. D., Proudfoot J. R., Grozinger K. G., Cullen E., Kapadia S. R., Patel U. R., Fuchs V. U., Mauldin S. C., Vitous J., Behnke M. L., Klunder J. M., Pal K., Skiles J. W., McNeil D. W., Rose J. M., Chow G., Skoog M. T., Wu J. C., Rosenthal A. S., Adams J. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J. Med. Chem. 34:1991;2231-2241.
11. Kellam P., Larder B. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69:1995;669-674.
12. Kleim J.-P., Bender R., Billhardt U. M., Meichsner C., Riess G., Rösner M., Winkler I., Paessens A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37:1993;1659-1664.
13. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 200:1994;696-701.
14. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Rösner M., Rübsamen-Waigmann H., Kaiser R., Wichers M., Schneweis K. E., Winkler I., Riess G. Preclinical evaluation of HBY 097, a new nonnucleoside inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39:1995;2253-2257.
15. Kleim J.-P., Rösner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA. 93:1996;34-38.
16. Larder B. A. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:1992;2664-2669.
17. Larder B. A., Coates K. E., Kemp S. D. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:1991;5232-5236.
18. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P. J., Mo H. M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G. R., Ho D. D., Boucher C. A. B., Leonard J. M., Norbeck D. W., Kempf D. J. Nature Med. 2:1996;760-766.
19. Moutouh L., Corbeil J., Richman D. D. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc. Natl. Acad. Sci. USA. 93:1996;6106-6111.
20. 3.
21. IIIB. J. Virol. 70:1996;3698-3705.
22. Richman D., Shih C. K., Lowy I., Rose J., Prodanovich P., Goff S. P., Griffin J. Human immmunodeficiency virus mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA. 88:1991;11241-11245.
23. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C. K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
24. Romero D. L., Morge R. A., Genin M. J., Biles C., Busso M., Resnick L., Althaus I. W., Reusser F., Thomas R. C., Tarpley W. G. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: Structure-activity relationships of novel substituted indole analogues and the identification of 1-[5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]- pyridinyl]piperazine monomethansulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36:1993;1505-1508.
25. Schinazi R. F., Larder B. A., Mellors J. W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 4:1996;95-107.
26. Tantillo C., Ding J., Jacobo-Molina A., Nanni R. G., Boyer P., Hughes S. H., Pauwels R., Andries K., Janssen P. A. J., Arnold E. Locations of Anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:1994;369-387.
27. Tisdale M., Myers M., Maschera B., Parry N. P., Oliver N. M., Blair E. D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1995;1704-1710.
28. Winslow D. L., Garber S., Reid C., Scarnati H., Baker D., Rayner M. M., Anton E. D. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS. 10:1996;1205-1209.